Brief: Biosenic To Potentially Receive Royalty Rates On Net Sales Up To 25%
May 24 (Reuters) - Bone Therapeutics SA BIOS.BR :
* BIOSENIC TO POTENTIALLY RECEIVE ROYALTY RATES ON NET SALES
UP TO
25%
* BIOSENIC AND PLURISTYX AIM TO FURTHER NEGOTIATE TERMS AND
CONDITIONS WITH A VIEW ON COMPLETING A FINAL AGREEMENT AND TO
FULLY EXECUTE IT BY Q3 2023
Source text for Eikon: ID:nGNE2Ggw2Z
Further company coverage: BIOS.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Biosenic SA
See all newsBrief: Biosenic Says Enterprise Court Of Nivelles Approves Co's Restructuring Plan
Brief: Biosenic Anticipates Having Sufficient Cash To Carry Out Its Business Objectives Until Q3 2024
Brief: BioSenic Patent Granted In Canada For Broader Protection Of ATO Therapeutic Platform
Brief: Biosenic Files For Additional Patent Protection For Osteoarthritis Drug
Brief: BioSenic Signs New Binding Term Sheet With Phebra PTY Ltd